Abstract:The recent wide spreading of the H5N1 avian influenza virus (AIV) in Asia, Europe and Africa and its ability to cause fatal infections in human has raised serious concerns about a pending global flu pandemic. Neuraminidase (NA) inhibitors are currently the only option for treatment or prophylaxis in humans infected with this strain. However, drugs currently on the market often meet with rapidly emerging resistant mutants and only have limited application as inadequate supply of synthetic material. To dig out helpful information for designing potent inhibitors with novel structures against the NA, we used automated docking, CoMFA, CoMSIA, and HQSAR methods to investigate the quantitative structure–activity relationship for 126 NA inhibitors (NIs) with great structural diversities and wide range of bioactivities against influenza A virus. Based on the binding conformations discovered via molecular docking into the crystal structure of NA, CoMFA and CoMSIA models were successfully built with the cross-validated q 2 of 0.813 and 0.771, respectively. HQSAR was also carried out as a complementary study in that HQSAR technique does not require 3D information of these compounds and could provide a detailed molecular fragment contribution to the inhibitory activity. These models also show clearly how steric, electrostatic, hydrophobicity, and individual fragments affect the potency of NA inhibitors. In addition, CoMFA and CoMSIA field distributions are found to be in well agreement with the structural characteristics of the corresponding binding sites. Therefore, the final 3D-QSAR models and the information of the inhibitor–enzyme interaction should be useful in developing novel potent NA inhibitors.

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico

Develop integration modeling approach for discovery neuraminidase inhibitors in silico based on pharmacophore and CoMSIA models

Discovery of Neuraminidase Inhibitors based on 3D-QSAR, Molecular Docking and MD Simulations

Qsar and Pharmacophore Studies of Thiazolidine-4-Carboxylic Acid Derivatives As Novel Influenza Neuraminidase Inhibitors Using Hqsar, Topomer Comfa and Comsia

Molecular Docking, 3d-Qsar Studies, And In Silico Adme Prediction Of P-Aminosalicylic Acid Derivatives As Neuraminidase Inhibitors

QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network

QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR

Chemical Structural Characterization And Design Of Influenza Neuraminidase Inhibitors Using Three-Dimensional Holographicvector Of Atomic Interaction Field Through Quantitative Structure-Activity Relationship Studies

Pharmacophore Modeling, 3D‐QSAR Studies, and In‐silico ADME Prediction of Pyrrolidine Derivatives As Neuraminidase Inhibitors

2D-QSAR Study of Carbocyclic Derivates Neuraminidase Inhibitors

Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors

Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors

QSAR studies on influenza neuraminidase inhibitors of cyclohexenes

Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.

QSAR Studies on Flavonoids Derivatives As Potent Neuraminidase Inhibitors

Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

Docking and 3D QSAR Study of Thiourea Analogs As Potent Inhibitors of Influenza Virus Neuraminidase.

QSAR Modeling and Molecular Interaction Analysis of Natural Compounds As Potent Neuraminidase Inhibitors

Three Dimensional Quantitative Structure-activity Relationship of Cyclohexene Neuraminidase Inhibitors